A Phase 2 Study of osimertinib in combination with selumetinib in EGFR inhibitor naive advanced EGFR mutant lung cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Dana-Farber Cancer Institute
Start Date
June 13, 2018
End Date
November 30, 2025
Administered By
Duke Cancer Institute
Awarded By
Dana-Farber Cancer Institute
Start Date
June 13, 2018
End Date
November 30, 2025